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CD4+ testing is the most predictable indicator of HIV disease 
progression, and owing to limited resources is widely used to 
determine whether a patient is eligible for antiretroviral therapy 
(ART). Currently, in settings where it is available, CD4+ testing is 
used to determine whether a patient is eligible for ART, and it is more 
reliable in determining ART eligibility than symptomatic staging.[1,2] 
Patients who do not have reliable on-site access to testing must often 
make numerous visits to healthcare facilities for testing blood draws, 
receiving test results, and routine clinical care visits due to sample 
and result transportation to and from centralised testing facilities. 
Furthermore, it has been suggested that up to 80% of patients are lost 
to follow-up before ART initiation.[3]
To overcome some of the challenges associated with centralised 
laboratory testing and patient loss to follow-up, high-quality point-
of-care (POC) diagnostic technologies are available to alleviate critical 
testing needs in facilities lacking on-site CD4+ testing and provide 
same-day test results.[4] Firstly, POC CD4+ technologies have the 
potential to increase patient access to CD4+ testing by reducing test 
turnaround time, allowing for more immediate clinical decisions, 
reducing patient loss to follow-up, and increasing the number of patients 
initiating ART. [5,6] Secondly, POC technologies can reduce the burden of 
managing an extensive sample transportation network that cannot fully 
meet patient need and a growing network of conventional instruments 
that are increasingly difficult to maintain. Thirdly, providing POC 
testing administered by personnel with minimal technical training can 
make remote healthcare facilities more self-sufficient and allow for 
efficient task-shifting of testing and related tasks.[7]
Objectives
In 2012, the Free State Department of Health in South Africa (SA) 
implemented the Alere Pima POC CD4+ technology at 30 healthcare 
facilities. These technologies are used exclusively to determine ART 
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Background. Point-of-care (POC) CD4+ technologies have the potential to increase patient access to treatment and care through rapid 
testing and result delivery at or close to where patients seek care. South African (SA) guidelines suggest the use of CD4+ testing to prioritise 
patients most in need of antiretroviral therapy (ART) and to support identification of patients with advanced HIV disease and opportunistic 
management of patients on ART. Understanding the patient impact of implementing POC CD4+ testing in the intended setting and 
operated by lower cadres of healthcare worker or non-professional healthcare facility staff will provide valuable insight into the appropriate 
use and placement of POC CD4+ technologies throughout SA.
Objectives. To determine the patient impact (turnaround time of tests, loss to follow-up, and proportions of eligible patients proceeding 
to the next steps in the testing and treatment cascade) of implementing POC CD4+ testing technologies compared with conventional 
laboratory-based CD4+ testing.
Methods. This retrospective cohort study included all HIV-positive adults from 30 healthcare facilities in Free State Province, SA. Healthcare 
facilities were placed into two groups (POC and laboratory referral) using a stratified randomisation technique based on the presence of 
a POC CD4+ technology and minimal ART volumes. Patients who received a CD4+ test prior to ART initiation between September 2012 
and September 2014 were included. Data were collected from patient charts and the POC devices.
Results. For new patients, the average time from HIV diagnosis and CD4+ testing was reduced from 7.6 days in the laboratory referral group 
to 4.5 days in the POC group, a decrease of almost 60%. Additionally, 59.6% of patients in the POC group received their HIV diagnosis 
and CD4+ test result on the same day, compared with 37.5% in the laboratory referral group (risk ratio (RR) 1.49; 95% confidence interval 
(CI) 1.01 - 2.18). Fewer patients were lost between HIV diagnosis and CD4+ testing (2.7% v. 8.6%) (RR 0.02; 95% CI 0.05 - 0.78) in the 
POC group. The average test error rate across the study time period was 8.4%; however, the error rate remained <5% for the final 5 months 
of the study.
Conclusions. Introduction of the Alere Pima POC CD4+ technology in the Free State, operated by nurses and lay counsellors, was 
associated with positive patient outcomes across all parameters analysed. While this study highlighted an effective conventional laboratory 
network, a full costing and affordability analysis coupled with patient impact and access data from this study will provide further insight 
into the potential deployment strategies of POC CD4+ technologies in SA.
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eligibility of HIV-positive patients and are typically operated by nurses 
and lay counsellors. The primary objective and research question of 
this study was to determine the patient impact (turnaround time 
of tests, loss to follow-up, and proportions of eligible patients 
proceeding to the next steps in the testing and treatment cascade) 
of implementing POC CD4+ testing technologies compared with 
conventional laboratory-based CD4+ testing. Assessing the potential 
patient impact of POC CD4+ testing in the intended healthcare 
facility setting operated by lower cadres of healthcare facility staff will 
provide valuable insight into the appropriate and possible placement 
and use of POC CD4+ technologies throughout SA.
Methods
Study setting
Healthcare facilities with and without POC CD4+ were randomly 
placed into two groups using a stratified randomisation technique. 
A total of 235 publicly supported Department of Health facilities were 
considered for selection. To ensure that each healthcare facility included 
contributed relatively similar proportions of patient data, we stratified 
the random facility selection to include only those healthcare facilities 
with >100 pre-ART patients during the previous year. All 30 healthcare 
facilities with Pima technology were among the 135 healthcare facilities 
meeting these volumes. Fifteen of the 30 healthcare facilities with Pima 
technology were randomly selected to make up the POC group. Fifteen 
of the remaining 105 healthcare facilities without Pima technology 
were randomly selected to make up the laboratory referral group. 
Healthcare facilities in both groups were widely distributed throughout 
the province, covering 14 of the 19 municipalities.
Study design
This was a retrospective cohort study reviewing data from all HIV-
positive adults aged ≥18 years who received a CD4+ test prior to ART 
initiation from each of the 30 selected healthcare facilities. The Alere 
Pima POC CD4+ technology implementation began in March 2012 
and was completed in the Free State in September 2012; only patients 
with CD4+ tests after September 2012 in both groups were therefore 
included. Data collection was conducted in September 2014 with data 
included from the previous 2 years for both groups. Patient charts 
were the primary tools used for data collection, while CD4+ testing 
registers and ART registers were also consulted. Sex, age, clinic visit 
dates, CD4+ test result and ART initiation status were captured for 
each patient. No personal identifiers were collected from patients. 
Records with inaccurate dates were corrected upon confirmation 
from the healthcare facility or excluded from analysis. In addition, 
primary raw data from the Alere Pima devices were downloaded 
when available to find out the percentage and types of errors 
encountered by healthcare facilities in the POC group as well as daily 
control bead tests run and operator volumes and errors. Errors can 
be due to operator or device malfunctions and are fatal, therefore 
requiring a repeat test. Internal control bead cartridges, consisting of 
one low CD4+ count and one normal CD4+ count cartridge, should 
be run each day prior to patient testing.
Data analysis
Primary parameters measured included retention and loss to follow-
up along the testing and treatment cascade as well as time between 
steps in the testing and treatment cascade. Medians (interquartile 
ranges (IQRs)) and percentages were used for descriptive comparisons 
of values. Retention and loss-to-follow-up parameters were analysed 
using a univariate logistic model to estimate the risk ratios (RRs) 
and 95% confidence intervals (CIs). Regression coefficients were 
estimated using generalised estimating equations, accounting for 
patient clustering by healthcare facility. Robust standard errors were 
used to allow for different variances between groups. We used the 
exchangeable working correlation matrix, which assumes equal 
correlations between all clusters. A log link function and the Poisson 
distribution were used with a contrast statement to directly estimate 
RRs. Not all patients had complete records; retention along the 
testing and treatment cascade was therefore calculated using patient 
records that contained all necessary data for the specific metric. If a 
required date or information was absent, the patient was excluded 
from that specific analysis.
Patients were considered lost to follow-up if they: (i) did not 
receive their CD4+ test result and did not return to the healthcare 
facility within 90 days; (ii) did not initiate ART (if eligible) and did 
not return to the healthcare facility within 90 days; or (iii) did not 
return to the healthcare facility within 90 days.
The SA ART guidelines changed in the middle of this study and 
were incorporated into the analysis. The ART eligibility criteria 
changed from a threshold of 200 cells/µL to 350 cells/µL in March 
2013. During the study period, patients were considered eligible for 
ART initiation with an absolute CD4+ count ≤200 cells/µL before 
March 2013 and ≤350 cells/µl after March 2013.
Data were entered into Excel version 16.16.15 (Microsoft Corp., 
USA) and analysed using SAS version 9.3 (SAS Institute, USA) and 
GraphPad Prism version 6.0 (GraphPad Software Inc., USA). Two 
researchers independently analysed and confirmed the results. The 
protocol for the study was reviewed and approved by the Ethics 
Committee of the University of the Free State and the Free State 
Department of Health and received a protocol exemption from the 
Chesapeake IRB (USA) (ref. no. Pro00010543).
Results
Study demographics
A total of 1 491 patients were included in the study. Overall, 66.5% 
of the patients were female (Table 1). Approximately 50% of enrolled 
patients were between the ages of 30 and 45 years, while the median 
(IQR) age was 35 (29 - 43) years. The median CD4+ count was 
314 cells/µL and the median CD4+ count at ART initiation 243 cells/
µL. Of patients with World Health Organization (WHO) staging 
documented (n=1 153), almost 70% were WHO stage 1 or 2 at 
presentation for CD4+ testing. In the POC group, the median CD4+ 
count was 327 (184 - 504) cells/µL), while the median CD4+ count at 
ART initiation for eligible patients was 240 (125 - 343) cells/µL. In the 
laboratory referral group, the median CD4+ count was 298 (152 - 463) 
cells/µL, while the median CD4+ count at ART initiation for eligible 
patients was 245 (115 - 342) cells/µL. These demographic results were 
not significantly different between the two groups. Approximately 
52% of patients in the POC group and 59% of patients in the 
laboratory referral group were eligible for ART initiation (Fig. 1).
Patient impact outcomes
The median times between HIV diagnosis, CD4+ sample taken, 
CD4+ test completed and result received were ≤1 day for both 
groups, with no significant differences between the groups. The 
proportion of patients who received their CD4+ test result was >95% 
in both groups; however, more patients in the POC group than in the 
laboratory referral group received their result on the day of testing 
(83.5% v. 64.1%; RR 1.25; 95% CI 1.01 - 1.54; p=0.04) (Fig. 2A).
Comparable or improved patient impact was observed in the 
POC group compared with the laboratory referral group across 
most parameters analysed (Fig. 2B). Approximately 60% of patients 
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received their HIV diagnosis and CD4+ test result on the same day 
in the POC group compared with <40% in the laboratory referral 
group (RR 1.49; 95% CI 1.01 - 2.18; p=0.04). There was no significant 
difference in the proportion of eligible patients initiated on ART 
between the two groups. When focusing only on ART-eligible 
patients, we found that more patients received their CD4+ test result 
and were retained on ART for at least 6 months in the POC group 
than in the laboratory referral group (Fig. 2C).
Higher proportions of patients were retained in the testing and 
treatment cascade when tested by POC compared with laboratory 
referral (Fig. 2B). Loss to follow-up was significantly higher before 
CD4+ test results were received in the laboratory referral group 
compared with the POC group (8.6% v. 2.7%; RR 0.20; 95% CI 0.05 - 
0.78; p=0.02). Although higher proportions of patients in the 
laboratory referral group were lost to follow-up between determining 
ART eligibility and initiation, as well as after ART initiation, results 
were not statistically significant.
We next wanted to find out whether the observed changes in patient 
impact outcomes were due to early excitement about and attention to 
introducing a new technology to the healthcare facilities. Data were 
separated between the 2 years of the study for both groups, October 
2012 - September 2013 and October 2013 - September 2014. For the 
POC group, although few samples were tested, eligible, and included 
in the first year, most patient impact parameters remained the same 
or improved in the second year of testing (data not shown).
Quality control of the POC CD4+ technology
The total Pima error rate for all healthcare facilities providing 
primary device data was 8.43%. The most prevalent errors observed 
were invalid test error 850 (25.2%), 880 (12.7%) and 910 (10.9%) 
(Fig. 3A). These three error types accounted for almost 50% of all 
errors. Manufacturer guidance suggests that invalid test error 850 
and 880 can be either operator or equipment related, whereas invalid 
test error 910 is most often operator-related. Seventy percent of 
healthcare facilities had error rates <10% for the total time period 
analysed. Interestingly, the five highest-volume healthcare facilities 
had error rates <10% (Fig. 3B).
Although these error rates were higher than the minimal 
manufacturer-suggested error rate threshold of 5%, we investigated 
whether performance improved over time. When the Pima 
technology is initially implemented, before healthcare facility staff 
become familiar with the technology, error rates can be higher. 
Indeed, when we analysed the data across time we saw that error 
rates dropped progressively. Since September 2013, error rates 
have remained at or below the minimal error rate threshold of 
5% (Fig. 3C). Four months were excluded from this analysis when 
healthcare facilities experienced stock-outs and were unable to test 
patients.
We also reviewed the regularity of running both the low and 
normal daily internal controls. Five out of the 13 healthcare facilities 
with data consistently ran both low and normal controls on <95% 
of testing days. The remaining eight healthcare facilities ran both 
the low and normal controls on <30% of testing days. Interestingly, 
however, 10 out of the 13 healthcare facilities ran at least one control 
on >80% of patient testing days.
Healthcare cadres operating the POC CD4+ technology
The POC CD4+ devices were placed in the ART clinics rather than 
in facility laboratories and were operated primarily by counsellors 
or nurses (Fig. 4). Counsellors conducted ~70% of all Pima tests 
and nurses ~15%. Although counsellors and professional nurses 
Table 1. Study patient demographics
Total POC Laboratory referral
All patients enrolled, N 1 491 811 680
Female, % 66.5 67.3 65.6
Age (years), median (IQR) 35 (29 - 43) 35 (29 - 43) 35 (29 - 44)
Age 30 - 45 years, % 50.7 52.0 49.1
WHO stage, %
1 43.0 42.0 44.1
2 25.8 28.6 22.7
3 27.4 26.3 28.7
4 3.8 3.2 4.5
CD4+ count (cells/µL), median (IQR) 314 (171 - 488) 327 (184 - 504) 298 (152 - 463)
CD4+ count (cells/µL) at ART initiation, median (IQR) 243 (119 - 343) 240 (125 - 343) 245 (115 - 342)
POC = point of care; IQR = interquartile range; WHO = World Health Organization; ART = antiretroviral therapy.
1,491 HIV-positive patients 
enrolled and included
811 patients CD4 tested by 
POC
680 patients CD4 testing by 
laboratory referral
780 (96.2%) patients 
received their CD4 test result
592 (87.1%) patients 
received their CD4 test result
402 (51.5%) patients were 
eligible for ART
350 (59.1%) patients were 
eligible for ART
348 (86.6%) eligible patients 
were initiated on ART
305 (87.1%) eligible patients 
were initiated on ART
Figure 1
HIV-positive patients enrolled and included,
N=1 491
Patients CD4+ tested by POC,
n=811
Patients who received their CD4+ 
test result,
n=780 (96.2%)
Patients eligible for ART,
n=402 (51.5%)
Eligible patients initiated on ART,
n=348 (86.6%)
Patients CD4+ tested by 
laboratory referral,
n=680
Patients who received their CD4+ 
test result,
n=592 (87.1%)
Patients eligible for ART,
n=350 (59.1%)
Eligible patients initiated on ART,
n=305 (87.1%)
Fig. 1. Flow chart of retention along the testing and treatment cascade from 
CD4+ testing to ART initiation. (ART = antiretroviral therapy; POC = point 
of care.)
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conducted >85% of all Pima tests, their combined error rate was 
<7.5%. The error rate for counsellors was 6.8%. Of healthcare cadres 
that conducted >100 tests, registered nurses had the highest error 
rate of 10.1%.
Discussion
Introduction of the Alere Pima POC CD4+ technology in the 
Free State was associated with positive patient outcomes across 
all parameters analysed. Patients received their CD4+ test result 
earlier than they did when using the conventional referral network. 
A higher proportion of patients received a CD4+ test result, and 
a higher proportion of ART-eligible patients initiated ART. In 
addition, a lower proportion of patients were lost to follow-up across 
all time periods considered, including between HIV diagnosis and 
CD4+ test, between CD4+ test and ART initiation, and overall 
throughout the study. Although POC CD4+ on-site testing improved 
POC group                          Laboratory referral group
Same day
1 day
2 days
3 days
4 days
≥5 days
A
B
0                25                50                75                100
Patients receiving CD4+ test result
Same-day HIV diagnosis and CD4+ test
Same-day HIV diagnosis and CD4+ results received
LTFU between HIV diagnosis and CD4+ test
LTFU between CD4+ test and ART initiation
LTFU after ART initiation
RR (95% CI)
1.08 (0.98 - 1.20)
1.34 (0.98 - 1.83)
1.49 (1.01 - 2.18)*
0.20 (0.05 - 0.78)*
0.59 (0.22 - 1.60)
0.65 (0.39 - 1.08)
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Fig. 2. Patient impact outcomes: (A) distribution of turnaround times between CD4+ testing and result received for each group; (B) proportion of patients 
retained or lost along the testing and treatment cascade; and (C) proportion of ART-eligible patients retained for at least 6 months along the testing and 
treatment cascade. (POC = point of care; LTFU = lost to follow-up; ART = antiretroviral therapy; RR = risk ratio; CI = confidence interval; *p<0.05.)
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outcomes, it is important to note that the 
performance of the conventional referral 
network provided good access to testing, 
with lower turnaround times and improved 
patient impact parameters compared with 
conventional referral networks observed in 
studies outside SA.[8-11]
The WHO recently released recom-
mendations suggesting the uptake of 
‘treat all’ for all HIV-positive patients.[12] 
As countries clinically, logistically and 
financially consider implementing ‘treat all’ 
widely, POC CD4+ may help to prioritise 
patients in most need of ART, particularly 
in settings with unpredictable drug supplies. 
Furthermore, SA guidelines suggest the 
use of CD4+ testing at ART initiation and 
to support HIV disease and opportunistic 
infection management of patients on ART. 
POC testing may allow for wider decentrali-
sation of HIV care, expedited clinical 
decisions and self-sufficient facilities, thus 
further improving the health system.[7]
While it is worth noting that the present 
work was an evaluation of programmatic 
implementation of POC CD4+ and not 
designed as a study, the results were consistent 
with previous studies conducted in SA. One 
study found that patients with access to 
POC CD4+ were more likely to return for 
further care (RR 1.25).[13] Additionally, two 
randomised controlled trials found that 
ART-eligible patients who received a POC 
CD4+ test were significantly more likely 
to initiate ART than those who received a 
laboratory-based CD4+ test.[14,15] Rosen et 
al.[15] also found that earlier ART initiation 
in patients using POC CD4+ did not result 
in greater attrition after initiation compared 
with the standard of care. Finally, similar 
time reductions were observed between 
HIV diagnosis, CD4+ staging and ART 
initiation. [14,16] The present study highlights 
that the previous research findings are 
consistent and applicable in a provincial 
public implementation programme.
The results observed are not as significant 
as we expected, or very different compared 
with results from other countries.[9] This 
is probably due to an optimised and 
efficient CD4+ sample collection and result 
delivery system established by the National 
Health Laboratory Service as well as strong 
national infrastructure to allow for swift 
transport of samples. Furthermore, many 
of the healthcare facilities in the laboratory 
referral group were within 100 km of their 
reference CD4+ laboratory. In fact, 7 of the 
15 healthcare facilities in the laboratory 
referral group were within 25 km of their 
reference CD4+ laboratory. It would there-
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fore be worthwhile to find out whether the impact of POC CD4+ 
testing would be more significant in rural healthcare facilities further 
from their reference CD4+ laboratory.
While this and other studies clearly emphasise superior patient 
impact performance of POC CD4+ technologies compared with 
conventional laboratory-based testing, the cost-effectiveness and 
affordability of implementing this programme in the light of new 
guidelines are unclear. POC CD4+ has been shown to be cost-
effective in Mozambique;[17] however, no similar study has been 
conducted in the SA context. A conventional and POC tiered 
approach has been suggested,[18,19] but the costs associated with both 
testing types are not sufficiently clear to indicate the affordability 
of each scenario in SA. Additional cost-effectiveness, costing and 
modelling work would be beneficial to determine the implications of 
POC CD4+ implementation into the national network in SA.
Study limitations
This study has several limitations. It was an observational 
retrospective programmatic implementation evaluation and therefore 
lacked the strength of a randomised controlled trial. In designing the 
study, we sought to limit sources of bias through randomly selecting 
facilities, consecutively enrolling all patients who matched the 
inclusion criteria, and maintaining the same time periods for both 
groups. Additional confounders may have occurred that were not 
incorporated into the final analysis. Fortunately, data management 
was strong and patient records were typically complete.
Conclusions
POC CD4+ improves timeliness and linkage to ART, but POC 
technologies are not the solution to all systems challenges. Although 
error rates were reduced over time to <5%, refresher training and 
routine monitoring would improve the testing system. Furthermore, 
the POC CD4+ technologies were not enrolled in any quality 
assurance programme for proficiency testing or monitored remotely 
using connectivity. Additional strengthening of the supply chain 
network, service and maintenance, and clinical guidance could 
further increase the observed patient impact. Implementation of 
POC CD4+ technologies will support faster, high-quality test result 
delivery and linkage in SA, while future research highlighting the 
patient impact and cost-effectiveness of POC CD4+ technologies 
in the context of advanced HIV disease identification would be 
beneficial.
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Fig. 4. Proportion of tests conducted by different operator cadres.
